- Home
- MRK vs GILD Comparison
MRK vs GILD Comparison
Compare MRK & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRK | GILD |
|---|---|---|
| Founded | 2000 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 173.9B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | MRK | GILD |
|---|---|---|
| Price | $115.44 | $138.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 18 |
| Target Price | $125.59 | ★ $148.39 |
| AVG Volume (30 Days) | ★ 6.7M | 4.9M |
| Earning Date | 04-30-2026 | 04-24-2026 |
| Dividend Yield | ★ 2.88% | 2.35% |
| EPS Growth | 8.01 | ★ 1684.21 |
| EPS | ★ 7.28 | 6.78 |
| Revenue | ★ $65,011,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $3.73 | $4.65 |
| Revenue Next Year | $5.42 | $5.96 |
| P/E Ratio | ★ $16.23 | $20.62 |
| Revenue Growth | 1.31 | ★ 9.98 |
| 52 Week Low | $75.40 | $95.30 |
| 52 Week High | $125.14 | $157.29 |
Technical Indicators
Market Signals| Indicator | MRK | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 44.68 |
| Support Level | $113.27 | $133.89 |
| Resistance Level | $124.57 | $142.33 |
| Average True Range (ATR) | 2.85 | 3.27 |
| MACD | -0.44 | 0.21 |
| Stochastic Oscillator | 7.86 | 50.88 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).